Ann: Trading Halt, page-437

Perhaps “the matters” are regarding further data required by the FDA?

From the transcript of the Q4 2020 results call on 27th August Silviu Itescu says
“In addition, we have plans to move forward in adults with steroid-refractory acute graft versus host disease. These patients with the most severe forms of the disease continue to have a high unmet need and poor survival.

Just this month, we convened an advisory meeting with key opinion leaders to develop a clinical trial design for a post-market study evaluating remestemcel in these high-risk patients”